Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Observational studies indicate a similar or higher probability of disease control, higher risk of non-relapse mortality (NRM), and similar overall survival (OS) with allogeneic stem cell transplantation (alloSCT), compared to autologous SCT, in relapsed or refractory non-Hodgkin lymphoma. Careful patient selection and utilization of reduced intensity conditioning (RIC) alloSCT may allow reduction in NRM. The optimal conditioning regimen and the roles of radioimmunotherapy, T cell depletion, and tandem SCT continue to be explored. Recent studies highlight comparable results with haploidentical SCT and cord blood SCT, thus providing alternate donor sources. Disease relapse and late effects continue to be major problems. Optimization of SCT techniques (e.g., improved graft-versus-host disease prophylaxis), post-transplant monitoring of minimal residual disease, and post-transplant maintenance, or pre-emptive therapy (e.g., with novel therapies) are emerging strategies to reduce the risk of relapse. Survivorship management using a multidisciplinary care approach, adoption of healthy lifestyle, and socioeconomic counseling are integral parts of a high-quality transplant program.

Original languageEnglish (US)
Pages (from-to)196-207
Number of pages12
JournalCurrent Hematologic Malignancy Reports
Issue number3
StatePublished - Jun 1 2016


  • Allogeneic stem cell transplantation
  • Autologous stem cell transplantation
  • Diffuse large B cell lymphoma
  • Follicular lymphoma
  • Mantle cell lymphoma
  • Non-Hodgkin lymphoma
  • Peripheral T cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma'. Together they form a unique fingerprint.

Cite this